Inactive Instrument
Five Prime Therapeutics, Inc. Share Price
Stocks
FPRX
US33830X1046
Biotechnology & Medical Research
| 1 day | +0.03% |
| Manager | Title | Age | Since |
|---|---|---|---|
James Bradner
CEO | Chief Executive Officer | 53 | - |
Peter Griffith
DFI | Director of Finance/CFO | 67 | - |
Jonathan Graham
LAW | General Counsel | 65 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 16/04/21 | Issuer sale | Director | 45,000 | 0.0966% | ||
| 16/04/21 | Free | Chief Financial Officer | 5,69,947 | 1.2238% | ||
| 16/04/21 | Issuer sale | Chief Executive Officer | 5,48,971 | 1.1788% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | +0.16% | - | - | 174.05Cr | |
| +2.41% | +0.29% | +39.41% | +72.14% | 6.47TCr | |
| -0.15% | +7.50% | +11.42% | +71.27% | 5.48TCr | |
| +0.57% | +4.60% | +7.71% | +90.93% | 5.35TCr | |
| +0.37% | +4.67% | +26.68% | +49.64% | 4.6TCr | |
| -1.21% | +2.32% | +21.50% | +118.33% | 4.29TCr | |
| -0.37% | +5.07% | +243.23% | +789.58% | 4.01TCr | |
| +0.05% | +0.21% | +18.06% | +48.50% | 3.35TCr | |
| +1.19% | -4.98% | +26.31% | -0.76% | 2.4TCr | |
| -0.38% | +5.68% | +38.39% | +28.35% | 2.37TCr | |
| Average | +0.25% | +2.41% | +48.08% | +140.89% | 4.26TCr | |
| Weighted average by Cap. | +0.39% | +2.73% | +46.02% | +142.84% |
Employees
51
